Established in 2018, Zen Biotechnology Group is a pioneering personalized healthcare enterprise with a leading vision. It is currently focused on the research and development of targeted cancer therapies and their accompanying diagnostics, dedicated to serving global cancer patients.
Headquartered in Singapore, renowned for its "Sky Garden," the company has a registered capital of 2 billion USD. Zen Biotechnology Group has been at the forefront of cancer research and treatment, designing more rational treatment plans and providing in-depth solutions to complex medical challenges. It is actively expanding into new medical fields, with a diversified portfolio in targeted therapy: wholly-owned subsidiaries include a Shanghai-based company focusing on precision oncology through high-throughput sequencing (NGS) and tumor genetic data analysis; a joint venture GMP facility in Dili, Timor-Leste, for targeted drug production; and a wholly-owned, fully automated EU-standard GMP pharmaceutical factory in Vientiane, Laos.
As a company guided by core values of innovation, integrity, friendship, responsibility, and collaboration, Zen Biotechnology Group integrates high-quality medical resources overseas, collaborating with over 80 global medical institutions to build a comprehensive diagnosis and treatment service system, ensuring long-term and stable cooperation.
With a mission to make cancer-targeted drugs affordable for all cancer patients, Zen Biotechnology Group aims to enable every cancer patient to access the most cost-effective targeted therapies through online purchasing, eliminating the various fees associated with cross-border pharmaceutical distribution such as tariffs, value-added tax, transaction costs, and wholesale-retail differences. The company is committed to providing a fully guaranteed, intermediary-free platform for cancer-targeted drugs.
Zen Biotechnology Group remains steadfast in its commitment to putting patients at the center, driven by its original intention to change the era and continually exploring ways to use science to transform lives, ensuring that the high cost of cancer treatment no longer hinders patients' paths to recovery. It aims to bring meaningful and profound changes to the healthcare industry, offering goodwill and hope to all cancer patients.
BioSpring is a vertically integrated pharmaceutical company focused on developing formulations through to commercialization, providing innovative solutions. Its Phase 1 facility is built to ICH-GMP standards, aiming to advance towards standardization and internationalization.
BioSpring.LTD from Laos and Zen Science from Singapore have announced the establishment of a new joint venture, BioZEN Health. BioZEN Health will specialize in the production and sales of high-value medical aesthetics products and health foods.
"Zen Science believes that Laos will play a central role as a transportation hub in the future of the Indochina Peninsula. This is Zen Science's small step towards future investments." — Eric Ju, Executive Director of Zen Science in Singapore.
Zen Science from Singapore has agreed to establish a new joint venture, BioZEN Health, in Laos. The new company will engage in the production and sales of high-value medical aesthetics products and health foods, along with providing related services locally.
Both companies have indicated that BioZEN Health was established in February this year with the aim to commence product sales by the second quarter of 2023. The transaction has reportedly obtained approval from regulatory authorities in Laos. Products from the new company, BioZEN Health, are expected to be marketed in mainland China, Southeast Asia, and Europe.
Eric Ju, Executive Director of Zen Science in Singapore, will assume the role of General Manager and Executive Director of the new joint venture, BioZEN Health, effective March 1st. Eric Ju previously served as the project manager for Zen Science in Greater China and was later appointed as head of the preparatory office for the BioZEN Health joint venture. Spencer Won has been appointed as Chief Marketing Officer of the joint venture by BioSpring.
BioZEN Health aims to leverage Zen Science's advanced biotechnology, existing drug registration and after-sales service management expertise, as well as BioSpring's mature production capabilities and relatively lower production costs in Laos, to achieve sustainable development.
2018-2024 Zen Science
Powered by GoDaddy